Plain-English translation of NCT06972628 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing Pluvicto, a radioactive medication that targets cancer cells in the body, for men with advanced prostate cancer that has spread to many bones. The study focuses on patients whose cancer has stopped responding to hormone treatments and who were not included in previous large trials. Researchers want to find the safest and most effective dose of this medication.
Many men with advanced prostate cancer that has spread widely to the bones were left out of earlier trials testing this treatment. This study fills that gap by specifically studying whether the medication works and is safe for this group of patients.
You likely qualify if…
You likely don't qualify if…
You would receive six doses of the radioactive medication as quick intravenous infusions, spaced six weeks apart over about five months. Throughout the study, you'll have regular blood tests, imaging scans (CT, bone scans, and possibly PET scans), and PSA checks to monitor how your body is responding. Follow-up visits and monitoring would continue every few months for up to five years to track your health and any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States